Lhasa Limited shared knowledge shared progress
Loading...

Publications

Jump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
Publications search results
TitlePublishedTypeProducts
Session 4 - The growing network of genotoxicityAOPs - Slidespdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - Slidespdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - Recording
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - Slidespdf file
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - Recording
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Slidespdf file
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Recording
Fragrance Database 2020.2.0 Release Notespdf fileVitic
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - Slidespdf fileKaptis
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - RecordingKaptis
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - Slidespdf file
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - Recording
Could purge calculations support your regulatory submissions? (Infographic)pdf fileMirabilis
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - Recording
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - Slidespdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - Slidespdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - Recording
Linking Evidence With AOPs To Produce Integrated Approaches to Testing and Assessment (IATA)pdf fileKaptis
Developing Federated QSAR Models for Secondary Pharmacologypdf file
The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7Derek NexusSarah Nexus
Derek and Sarah for Web 1.1 Installation Guidepdf file
Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data_EMGS Data Challenge 2020pdf fileKaptisDerek NexusVitic
Introducing the concept of virtual control groups into preclinical toxicology testingeTOXeTRANSAFE
Zeneth 8 Release Notespdf file
Zeneth 8 Installation Guidepdf file

© 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).